Full Library

Return to list of results

Valganciclovir Prophylaxis Extension from 3 to 6 Months in High Risk Pancreas Transplant Recipients Does Not Impact Incidence of Cytomegalovirus Infection at 12 months

RIS

Recommended format for most reference management software

BibTeX

Recommended format for BibTeX-specific software

Open in Zotero
View on zotero.org
Resource type
Journal Article
Authors/contributors
Title
Valganciclovir Prophylaxis Extension from 3 to 6 Months in High Risk Pancreas Transplant Recipients Does Not Impact Incidence of Cytomegalovirus Infection at 12 months
Abstract
Problem: Incidence and impact of CMV infection in pancreas-transplant recipients (PTRs) in the valganciclovir prophylaxis era has not be completely elucidated.
Publication
Clinical Transplantation
Date
2021-06-02
Journal Abbr
Clinical Transplantation
DOI
10.1111/ctr.14379
URL
https://onlinelibrary.wiley.com/doi/10.1111/ctr.14379
Accessed
6/2/21, 3:55 PM
ISSN
0902-0063, 1399-0012
Language
en
Library Catalog
DOI.org (Crossref)
Citation
Jorgenson, M. R., Marka, N., Leverson, G. E., Smith, J. A., & Odorico, J. S. (2021). Valganciclovir Prophylaxis Extension from 3 to 6 Months in High Risk Pancreas Transplant Recipients Does Not Impact Incidence of Cytomegalovirus Infection at 12 months. Clinical Transplantation. https://doi.org/10.1111/ctr.14379
ORGANISMS
Link to this record
https://www.transplantid.net/T4QIWMFE